Search Thermo Fisher Scientific
- Order Status
- Quick Order
-
Don't have an account ? Create Account
Past presentations from Gibco virtual stem cell event
Over the past nine years, we have hosted over 325 leading scientific presentations at the Gibco virtual stem cell event–now 5 Days of Stem Cells. Below is a complete list of presentations and speakers since 2013 with select presentations available*.
Share your research with >4,000 researchers worldwide!
If you'd like to share your latest discoveries at this renowned virtual stem cell conference, contact the event coordinator at 5daysofstemcells@thermofisher.com.
2021
| Presentation | Speaker | Affiliation |
|---|---|---|
| Rapid dissociation of 3D spheroids using the Rotea Counterflow Centrifugation System | Michael Akenhead | Thermo Fisher Scientific |
| Utilizing the Gibco™ CTS™ Rotea™ System, a versatile closed manufacturing system, for cell and gene therapy development | Emily Benz | ViaCyte |
| A fateful decision | Laurie Boyer | Massachusetts Institute of Technology |
| Development of humanized mouse models for biomedical research | Michael Brehm | University of Massachusetts Medical School |
| Beyond stem cells therapies: Mitochondria as a new living drug in regenerative medicine | Andrés Caicedo | Universidad San Francisco de Quito |
| Maturation strategies for iPSC cardiac 3D tissues and phenotypic correction of calmodulinopathy disease models using CRISPRi | Huang Chen-Yu | National Cheng Kung University |
| Stem cell-based approaches to study neurological disorders | Derek Dykxhoorn | University of Miami Miller School of Medicine |
| Using iPS-derived cells to produce functional human liver organoids | Ernesto Goulart | University of São Paulo |
| Adipose-derived stem cells as a cell source for cultivated meat production | Petra Hanga | University College London |
| Artificial cells: From therapy to regeneration | Mahdi Hasani | University of California Los Angeles |
| Human induced pluripotent stem cells: Applications in neurodevelopmental and neurodegenerative diseases | Youssef Hibaoui | University Hospital of Fribourg |
| De-risking preclinical drug development: simultaneous assessment of efficacy and toxicity | James Keck** | The Jackson Laboratory |
| Characterizing stems cells using Invitrogen antibodies | Jamuna KS | Thermo Fisher Scientific |
| Understanding and modifying cellular age-stage | Christian Nefzger** | University Queensland |
| Cell and gene therapies | Jan Nolta** | University of California Davis Health |
| Accelerating the future of stem cell research with connected automation | Sean Peschisolido & Sarah Yesford | Thermo Fisher Scientific |
| The growing concern of off-target effects: How to measure and minimize off-target effects in your genome editing experiments | Pandhita Pochanard | Thermo Fisher Scientific |
| Simplified online tools for CRISPR-Cas9 gene editing design and confirmation | Matt Poling | Thermo Fisher Scientific |
| In vitro characterization of mesenchymal stromal cells: Promising uses in spinal cord injury | Carolina Quintero Gil | Bioxcellerator |
| Challenges & hurdles for clinical application of iPSC in South Korea | Yeri Alice Rim | Catholic iPSC Research Center (CiRC) |
| Placental susceptibility to SARS-CoV-2 and its physiological impact on mesenchymal stem cells | Mairim Solis | Sistema Nacional de Investigación de Panamá |
| Advanced stem cell therapies for patients with kidney disease | Cathelijne van den Berg | Leiden University Medical Center |
| The importance of quality control assays for pluripotent stem cell line banks | Erik Willems | Thermo Fisher Scientific |
| Stem cells and genomics for precision cardiovascular medicine | Joseph Wu** | Stanford Cardiovascular Institute |
| Forming hearts and repairing hearts with hPSCs | Robert Zweigerdt** | Hannover Medical School |
| **Keynote presenter | ||
2020
2019
2018
2017
| Presentation | Speaker | Affiliation |
|---|---|---|
| Utilization of stem cells to crack motor neuron development and degeneration | Jun-An Chen** | Institute of Molecular Biology Academia Sinica |
| Organoid technology—from adult stem cells to miniature organs | Helmuth Gehart** | Hubrecht Institute for Developmental Biology and Stem Cell Research |
| Mammalian DNA methylation landscapes and human cancers | Alexander Meissner** | Max Planck Institute for Molecular Genetics |
| Human pluripotent stem cells in understanding genetic cardiovascular disease and effects of drugs | Christine Mummery** | Leiden University Medical Center |
| On the road to realizing tissue engineering’s transformative potential: multidisciplinary approach to accelerate bench-to-clinic transition | Nina Tandon and Ben Shepherd** | EpiBone Organovo |
| Eliminating inherent genome editing bottlenecks in iPSCs to build physiologically relevant disease models | Erik Willems** | Thermo Fisher Scientific |
| Gibco sera—driving quality and innovation in a dynamic market | Matthew Dallas and Chris Scanlon** | Thermo Fisher Scientific |
| Industry uses of human pluripotent stem cells | Stuart Chambers | Amgen |
| Custom-tailored cardiomyocytes: Directed differentiation of human pluripotent stem cells into defined atrial and ventricular cardiomyocyte subtypes | Lukas Cyganek | University of Göttingen |
| Comparison of the teratoma assay and in vitro surrogate tests for assessment of pluripotency of human pluripotent stem cells | Christian Freund | Leiden University Medical Center |
| Directed differentiation of hematopoietic cells from human pluripotent stem cells | Alessandra Giorgetti | Center for Regenerative Medicine in Barcelona |
| Examining the negative impacts of bioflavonoids on the DNA damage response and DNA repair mechanisms in mouse embryonic stem cells | Donna Goodenow | University of North Carolina at Charlotte |
| Mechanisms for assembling and resolving naïve pluripotency | Jacob Hanna | Weizmann Institute of Science |
| Pluripotent stem cell bioprocessing platforms for cell therapy manufacturing | Jahid Hasan | Cell and Gene Therapy Catapult |
| Identification of a high titer lentiviral production alternative to facilitate regenerative medicine therapies | Calley Hirsch | CCRM |
| Building inner ear organoids from human pluripotent stem cells through directed self-assembly | Karl Koehler | Indiana University School of Medicine |
| Integrated processes for derivation, expansion and differentiation of hiPSC to blood in IPS-Spheres™ cultures | Alan Lam | Bioprocessing Technology Institute (BTI) of Singapore |
| New monoclonal antibodies to defined cell surface proteins on human pluripotent stem cells | Andrew Laslett | Commonwealth Industrial and Scientific Research Organisation or CSIRO |
| Genomic profiling reveals novel PAX7 targets CD54, integrin α9β1 and SDC2, as markers for isolation of human ES/iPS cell-derived muscle progenitors | Alessandro Magli | University of Minnesota |
| Pluripotent stem cells to explore mechanisms and treatments of neuromuscular diseases | Cécile Martinat | I-Stem French Stem Cell Society |
| iPSC-derived neural cells for drug discovery of mitochondrial brain diseases | Alessandro Prigione | Max Delbrueck Center for Molecular Medicine (MDC) |
| New insights about Zika virus infection using iPS cells | Stevens Rehen | D'Or Institute for Research and Education (IDOR) & Institute of Biomedical Sciences, Federal University of Rio de Janeiro |
| Pancreatic progenitors: from the organ to the plate | Meritxell Rovira | Center for Regenerative Medicine in Barcelona |
| Braingineering’s human midbrain organoids as novel model for neurodegenerative diseases | Jens Christian Schwamborn | Braingineering Technologies SARL |
| Patient-specific hiPSCs for understanding diabetes disease mechanisms | Adrian Kee Keong Teo | IMCB, A*STAR SBS and LKC Medicine, NUS Medicine |
| Preparing for what’s next – keys to a successful career search | Sarah Gibson | Thermo Fisher Scientific |
| How to do an elevator pitch that will win you friends, admirers and maybe even funding | Kevin McCormack | California Institute for Regenerative Medicine |
| Journal publishing tools that make your research stand out | Rebecca Shumbata | Mary Ann Liebert, Inc. Publishers |
| How to get the most out of LinkedIn | Ania Wronski | Thermo Fisher Scientific |
| Physiological oxygen: historical and molecular perspective for stem cell culture | Mary Kay Bates | Thermo Fisher Scientific |
| New viral and non-viral platforms for T-cell engineering | Xavier de Mollerat du Jeu | Thermo Fisher Scientific |
| New Gibco B-27 Plus Neuronal Culture System—next generation media for superior neuronal survival and functionality | Navjot Kaur | Thermo Fisher Scientific |
| New tools for improved CRISPR gene-editing in stem cells | James Kehler | Thermo Fisher Scientific |
| Highly efficient stem cell engineering via Cas9 protein transfection | Xiquan Liang | Thermo Fisher Scientific |
| Comprehensive characterization of pluripotent stem cells | Suman Pradhan | Thermo Fisher Scientific |
| **Keynote presenter | ||
2016
| Presentation | Speaker | Affiliation |
|---|---|---|
| Genetic variability of ps-iPSC and related blood and fibroblasts—somatic mutations | Silke Rickert-Sperling** | Charité Medical Faculty and the Max Delbrück Center for Molecular Medicine Charité - Universitätsmedizin Berlin |
| Molecular elucidation and engineering of stem cell fate decisions | David Schaffer** | University of California, Berkeley |
| Using patient-derived iPSCs to model and treat inherited retinal degenerative blindness | Budd Tucker** | University of Iowa Carver College of Medicine |
| Optimization of your PSCs workflow | Jing He | Thermo Fisher Scientific |
| Initiatives to advance stem cell science and medicine at California’s $3 billion stem cell agency | Stephen Lin | California Institute for Regenerative Medicine |
| Partnering to advance regenerative medicine and cellular therapies | Morrie Ruffin Michael Werner | Adjuvant Partners Holland & Knight |
| Evolving your media system for modern stem cell applications | Rhonda Newman | Thermo Fisher Scientific |
| From bench to BLA—a review of common regulatory questions | Joyce Frey-Vasconcells Michael Mendicino Kelli Tanzella | Frey-Vasconcells Consulting, LLC Hybrid Concepts International Thermo Fisher Scientific |
| Precise generation of desired human cell-types from embryonic stem cells | Lay Teng Ang | Genome Institute of Singapore |
| Derivation of a spectrum of regional motor neuron phenotypes for hindbrain and spinal cord regenerative medicine | Randolph Ashton | University of Wisconsin Madison |
| Directed differentiation of induced pluripotent stem cells to hepatic stellate cells | Pau Sancho Bru | Institut D'Investigacions Biomediques August Pi I Sunyer (IDIBAPS) |
| Elucidating the physiological function of cellular PrPC using human iPS cell | Vijay Chandrasekar | Universitat Zurich |
| ‘HipSci' and the ‘Stem cell hotel’: innovative platforms for collaborative phenotyping | Davide Danovi | King's College London |
| Disease modelling in pluripotent stem cell-derived cardiomyocytes | Chris Denning | University of Nottingham |
| Human pluripotent stem cells for the study of enteric neuropathies | Faranak Fattahi | Memorial Sloan-Kettering Cancer Center and Weill Cornell Medicine |
| Transitioning to the clinic from proof of concept research: Challenges associated with converting research materials and methods to a clinical grade product. | Ben Fryer | University of Washington School of Medicine |
| Human PSC-based disease modeling to study X-linked dystonia-parkinsonism | William Hendriks | Harvard Medical School |
| Use of stem cell models to assess genetic change underlying neurodevelopmental disorders | Lachlan Jolly | The University of Adelaide |
| Building embryonic lineages | Leo Kurian | CECAD - Cluster of Excellence, Institute for Neurophysiology & Center for Molecular Medicine (CMMC), University of Cologne |
| Human umbilical cord mesenchymal cells and the treatment of bronchopulmonary dysplasia | Willie Lin | Meridigen Biotech Co., Ltd. |
| Stem cells for regeneration and rescue | Jeanne Loring | The Scripps Research Institute |
| First allogeneic mesenchymal stromal cell product approved in India for Buerger’s disease—an unmet medical need | Anish Sen Majumdar | Stempeutics Research |
| Transplanted human stem cell-derived interneuron precursors mitigate mouse bladder dysfunction and central neuropathic pain after spinal cord injury | Cory Nicholas | Neurona Therapeutics University of California, San Francisco |
| Exploring new avenues for cataract treatment using human pluripotent stem cells | Michael O’Connor | Western Sydney University University of Sydney, |
| Challenge toward clinical trial for spinal cord injury using iPS cell | Hideyuki Okano | Keio University School of Medicine Brain Science Institute RIKEN |
| Optimizing retinal cell differentiation of human pluripotent stem cells for large-scale disease modeling. | Alice Pébay | University of Melbourne |
| From urine to the study of metabolic disease—A patient-driven strategy to decipher PCSK9 roles and functions | Karim Si-Tayeb | l’institut du thorax INSERM |
| From millions to billions to trillions – translating your cell discovery into a cell product | Nick Timmins | CCRM, Canada |
| Regulation of autologous cell clinical interventions | Bernie Tuch | NSW Stem Cell Network |
| Immunomodulation and immunogenicity of human MSC-like cells: What did we learn from in vitro and in vivo studies? | Hans-Dieter Volk | Charité-Universitätsmedizin Berlin |
| Translating pluripotent stem cell therapies for focal brain disorders | Dustin Wakeman | RxGen, Inc. |
| Improved differentiation of human pluripotent stem cell-derived neurons through reduction of progenitor proliferation: impact on downstream applications | David Kuninger | Thermo Fisher Scientific |
| Analyzing stem cell populations using flow cytometry | Jolene Bradford | Thermo Fisher Scientific |
| Techniques and recommendations for colony selection and passage of iPSC | Chad MacArthur | Thermo Fisher Scientific |
| The matrix equation—solving for the best PSC culture goals | Rhonda Newman | Thermo Fisher Scientific |
| iPSC generation and validation: Ensuring the best materials for downstream applications | Rene Quintanilla | Thermo Fisher Scientific |
| Delivery solutions for robust CRISPR-based genomic editing in stem cells for disease model generation | Nektaria Andronikou | Thermo Fisher Scientific |
| **Keynote presenter | ||
2015
| Presentation | Speaker | Affiliation |
|---|---|---|
| Genome editing and stem cell engineering for disease modeling | Jon Chesnut** | Thermo Fisher Scientific |
| Probing disease mechanisms in ALS and ion-channel epilepsy using iPSCs, reprogramming and optogenetic approaches | Evangelos Kiskinis** | Northwestern University |
| Biomaterials for assembly of stem cell-derived human tissues | William Murphy** | University of Wisconsin |
| Epigenetic regulation in stem cells and reprogramming | Alexander Meissner | Harvard University Harvard Stem Cell Institute |
| Standardizing stem cell research | Alexander Meisner Ernest Wolvetang Tennielle Ludwig | |
| Differentiation of midbrain floor plate progenitors and dopaminergic neurons from human pluripotent stem cells | Soojung Shin | Thermo Fisher Scientific |
| Essential 8 Flex: Eliminating daily feeding in feeder-free, xeno-free PSC culture system | Matthew Dallas | Thermo Fisher Scientific |
| Antibodies for stem cell research | Kara Machledit | Thermo Fisher Scientific |
| Highly efficient genome editing and cell engineering in stem cells using CRISPR/Cas9 | Namritha Ravinder Shantanu Kumar | Thermo Fisher Scientific |
| Improved T cell function and in vivo engraftment of CAR-T cells expanded ex vivo with CTS Immune Cell SR | Angel Varela Rohena | Thermo Fisher Scientific |
| Pluripotent stem cell characterization methods | Deborah Tieberg | Thermo Fisher Scientific |
| Pluripotent stem cell culture systems: Identification of appropriate medium, matrix and passaging reagent | Rhonda Newman | Thermo Fisher Scientific |
| PSCs to cardiomyocytes in three steps | Alex Hannay | Thermo Fisher Scientific |
| Thermo Fisher Scientific’s cell therapy capabilities | Brian Newsom | Thermo Fisher Scientific |
| Optimizing retinal cell differentiation of human pluripotent stem cells for large-scale disease modeling | Alice Pébay | University of Melbourne |
| HOXA gene expression defines definitive fetal hematopoietic cells differentiated from human embryonic stem cells | Andrew Elefanty | Murdoch Children’s Research Institute |
| Muscle stem cells harboring basal levels of pluripotency genes are amenable to pluripotent conversion without using reprogramming factors or small molecules | Bipasha Bose | Yenepoya University |
| The use of modified mRNA to enhance the generation of induced neural precursor cells from adult human fibroblasts | Bronwen Connor | University of Auckland |
| Functional dissection of disease-associated chromosomal deletions with human iPSCs | Eirini Papapetrou | Icahn School of Medicine at Mount Sinai |
| Human oocyte as source of information to study cell pluripotency and reprogramming | Elena González Muñoz | Centro Andaluz de Nanomedicina y Biotecnología (BIONAND) |
| Standardized generation of patient-specific iPSC lines and scalable production of PSC-derived cardiomyocytes | Emily Titus | CCRM, Canada |
| In vitro quantification of the terminal differentiation potential of pluripotent stem cells | Ernst Wolvetang | University of Queensland |
| A novel PSC-based myogenic platform to explore treatment strategies for muscle diseases | Jérôme Chal | Harvard Medical School |
| The laminin protein family—key to stem cell culture | Jesper Ericsson | BioLamina |
| Variability of cardiomyocyte differentiation among human pluripotent stem cells: A practical screening approach | Katherine Santostefano | University of Florida Center for Cellular Reprogramming |
| Modeling predisposition to schizophrenia using hiPSCs | Kristen Brennad | Icahn School of Medicine at Mount Sinai |
| Dental pulp of the third molar: a new source of pluripotent-like stem cells | Maher Atari | Universitat Internacional de Catalunya |
| Generation of induced pluripotent stem (iPS) cell-derived cardiomyocytes for disease modeling and drug discovery | Nirupama Pike | Stem Cell Theranostics |
| Efficient generation of footprint-free patient-specific iPS cells and the application for drug screening | Noemi Fusaki | Keio University School of Medicine |
| Scalable xeno-free culture system for human induced pluripotent stem cells | Tiago Fernandes | Institute for Bioengineering and Biosciences |
| Tissue engineering of hiPSC for endothelial cell regeneration and cardiac repair | Ye Lei | National Heart Centre Singapore |
| Toward large-scale functional genomic studies through the automation of induced pluripotent stem cell derivation, expansion and differentiation | Daniel Paull | New York Stem Cell Foundation |
| Modeling eye diseases using human adult retinal pigment epithelium stem cells | Timothy Blenkinsop | Icahn School of Medicine at Mount Sinai |
| Combined stem cell transplantation and gene therapy on the regeneration of corticospinal axons after spinal cord injury | Stuart Hodgetts | University of Western Australia |
| **Keynote presenter | ||
2014
| Presentation | Speaker | Affiliation |
|---|---|---|
| The future of pluripotent stem cell banking | Jonathan Loh Yuin-Han | A*STAR Institute of Molecular and Cell Biology |
| Utility of gene expression signatures for the characterization of cellular identity | Alexander Meissner | Harvard Stem Cell Institute |
| Reprogramming cells to study mental disorders | Stevens Rehen | Institute of Biomedical Sciences, Federal University of Rio de Janeiro and D’Or Institute for Research and Education |
| Molecular engineering of biomaterial platforms for scalable stem cell manufacturing | David Schaffer | University of California at Berkeley |
| Using iPS cell technology to model human neurodegenerative diseases | Angel Raya | Center for Regenerative Medicine in Barcelona (CMRB) |
| Pluripotent stem cells to model human brain development | Chris Fasano | Neural Stem Cell Institute |
| Scalable production of human stem/progenitor cells in bioreactor systems | Claudia Lobato da Silva | Stem Cell Bioengineering and Regenerative Medicine Laboratory, Instituto Superior Técnico, Universidade de Lisboa |
| Deriving functional hepatocytes from pluripotent stem cells | David Hay | MRC Centre for Regenerative Medicine |
| Hematopoietic disease modeling using iPSCs | Deborah French | The Children's Hospital of Philadelphia |
| Development of chemically defined cell culture for human pluripotent stem cells | Guokai Chen | University of Macau, China |
| Culture adaptation of pluripotent stem cells: an in vitro model for oncogenesis | Ivana Barbaric | University of Sheffield |
| iPSCs for modeling disease in Africa | Janine Scholefield | CSIR Biosciences |
| Reversibility of the cellular aging physiology through an iPSC state : a new paradigm for human cell rejuvenation | Jean-Marc Lemaitre | Institute of Regenerative Medicine and Biotherapies, INSERM, Stem Cell Core Facility SAFE-iPSC |
| Derivation and function of clinical-grade human ESCs in Parkinson's disease monkey models | Jie Hao | Chinese Academy of Sciences |
| Knock-in gene correction in pyruvate kinase deficiency patient–derived iPSC, the most common metabolic erythroid disease | Jose Carlos Segovia | CIEMAT/CIBERER |
| Developing autologous cell therapy for macular degeneration using IPS cell–derived RPE tissue: a model for public-private partnership | Kapil Bharti | National Eye Institute, National Institutes of Health |
| Reprogramming somatic cells using the Sendai virus technology | Laurence Daheron | Harvard Stem Cell Institute |
| Mechanisms of reprogramming: applying lessons from mouse models to improve the efficiency of an iPSC core facility | Laurent David | Medical School of University of Nantes |
| Induced pluripotent stem cells: time for standards | Mathilde Girard | I-Stem |
| Pluripotency factors and cell lineage specification | Michael Puceat | French National Institute of Health and Medical Research, INSERM |
| The challenges and possible solutions for transferring cell therapy from the bench to the industry, while assuring high quality and manufacturing efficiency | Ohad Karnieli | Pluristem Therapeutics Inc |
| SCL/TAL1-mediated transcriptional network enhances megakaryocytic specification of human embryonic stem cells | Pedro Real | GENYO Centre for Genomics and Oncological Research: Pfizer-University of Granada-Andalusian Regional Government |
| Cellular immune therapy for virus-associated human malignancies and post-transplant infectious complications | Rajiv Khanna | QIMR Centre for Immunotherapy and Vaccine Development QIMR Berghofer Medical Research Institute |
| Developing a human embryonic stem cell based therapy for multiple sclerosis | Ren-He Xu | University of Macau |
| Developing a human ES cell derived dopamine neuron source for cell therapy in Parkinson's disease—from academic to translational research | Stefan Irion | MSKCC |
| Chromatin modifiers in reprogramming | Tamer Onder | Koç University |
| iPSC reprogramming from human blood using Sendai virus mediated gene transfer | Wenli Yang | University of Pennsylvania |
| Use of pluripotent stem cells to model premature aging syndromes | Xavier Nissan | CECS, I-Stem, AFM, Institute for Stem cell Therapy and Exploration of Monogenic diseases |
| Transcriptome profiling and stem cell-based therapies | Yi Sun | UCLA Institute for Stem Cell Biology and Medicine |
| Stage-specific grafting of hESC-derived midbrain dopamine neurons | Yosif Ganat | MSKCC |
| Pharmacological modulation of cell fates | Yu Wang | Chinese Academy of Sciences |
| Personalized disease model in dish - Starting with Parkinson’s Disease | Jing He Bo Peng | Thermo Fisher Scientific |
| Hands-free stem cell research: services to save you time | Carolyn Pettersson | Thermo Fisher Scientific |
| Cell therapy logistics—beyond the basics | Dan O’Donnell | Thermo Fisher Scientific |
| Trends and considerations for cell therapy development | Eric Roos | Thermo Fisher Scientific |
| Considerations for creating a disease model for Parkinson's disease using stem cells | Kurt Vogel | Thermo Fisher Scientific |
| Efficient cell specific differentiation systems for iPSC | Mohan Vemuri | Thermo Fisher Scientific |
| Antibody based tools and protocols for characterization of pluripotent stem cells | Nirupama Pike | Thermo Fisher Scientific |
| Considerations for the culture of pluripotent stem cells | Jennifer Crean | Thermo Fisher Scientific |
| Differentiate pluripotent stem cells to contracting cardiomyocytes in 3 easy steps | Alex Hannay | Thermo Fisher Scientific |
| Eliminate serum to gain control of your T cell research | Sandra Kuligowski | Thermo Fisher Scientific |
| Rapid induction of neural stem cells without the need for EB formation | Alex Hannay | Thermo Fisher Scientific |
| Score! A gene expression profile for your iPS lines | Deborah Tieberg | Thermo Fisher Scientific |
2013
| Presentation | Speaker | Affiliation |
|---|---|---|
| Genome editing to generate human cellular disease models | Chad Cowan** | Harvard University |
| Pluripotency and differentiation | Alexander Meissner** | Harvard University |
| Reprogramming human hematopoietic cells for regenerative medicine | Elias Zambidis** | Johns Hopkins University School of Medicine |
| Human pluripotent stem cell-derived dopaminergic neurons for screening | Xianmin Zeng | Buck Institute for Research and Aging; Xcell Science, Inc. |
| Transcriptional analysis during reprogramming at the single cell level. | Jose Polo** | Monash University |
| Hematopoietic differentiation of human pluripotent stem cells | Junfeng Ji | Zhejiang University |
| iPSC-dervied NSCs from Life Technologies Gibco Neural Induction Medium | Michael Edel** | Universitat de Barcelona |
| Using iPS cell technology to model human neurodegenerative diseases | Angel Raya** | IBEC, Barcelona |
| iPSCs for modeling disease in Africa | Janine Scholefield** | Councel for Scientific and Industrial Research (CSIR) |
| Parkinson’s Part I: Life Technologies and the Parkinson’s Institute collaborate to understand the molecular basis for Parkinson’s disease | Roland Leathers | Thermo Fisher Scientific |
| Parkinson’s Part II: Generation of induced pluripotent stem cells from Parkinson’s disease fibroblasts | Connie Lebakken | Thermo Fisher Scientific |
| Parkinson’s Part III: Generation and characterization of neural stem cells from Parkinson’s disease donor-derived iPSCs | Kun Bi | Thermo Fisher Scientific |
| Parkinson’s Part IV: Genome Editing of Parkinson’s Disease iPSCs Using GeneArtPrecision TAL Technology | Spencer Hermanson | Thermo Fisher Scientific |
| Considerations for culturing neural stem cells | Yiping Ya, Soojung Shin | Thermo Fisher Scientific |
| Considerations for culturing mesenchymal stem cells | Shayne Boucher | Thermo Fisher Scientific |
| Considerations for culturing pluripotent stem cells | Marian Piekarczyk | Thermo Fisher Scientific |
| Considerations for reprogramming pluripotent stem cells | Chad MacArthur | Thermo Fisher Scientific |
| Considerations for characterizing pluripotent stem cells | Rene Quintanilla | Thermo Fisher Scientific |
| CytoTune-iPS Sendai 2.0 Reprogramming Kit | Jennifer Crean | Thermo Fisher Scientific |
| TaqMan hPSC Scorecard Panel and data analysis software | Deborah Tieberg | Thermo Fisher Scientific |
| Essential 8 media and vitronectin | James Lovgren | Thermo Fisher Scientific |
| Cell Model Services for stem cell research | Carolyn Pettersson | Thermo Fisher Scientific |
| Products and services for neural differentiation | Alex Hannay | Thermo Fisher Scientific |
| Genome editing tools—GeneArt TALs & CRISPRs | Farzad Haerizadeh | Thermo Fisher Scientific |
| **Keynote presenter | ||
*Thermo Fisher Scientific and its affiliates are not endorsing, recommending, or promoting any use or application of products presented by third parties during this event. Information and materials presented or provided by third parties are provided as-is and without warranty of any kind, including regarding intellectual property rights and reported results. Parties presenting images, text, and materials represent they have the right to do so.
For Research Use Only. Not for use in diagnostic procedures.